What is the official website of Springer Health+ India ?

The official website of Springer Health+ India is https://springerhealthplus.com/.

What is Springer Health+ India's cybersecurity risk score?

Springer Health+ India has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Springer Health+ India experienced?

According to Rankiteo, Springer Health+ India currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Springer Health+ India been affected by any supply chain cyber incidents ?

According to Rankiteo, Springer Health+ India has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Springer Health+ India have SOC 2 Type 1 certification ?

According to Rankiteo, Springer Health+ India is not certified under SOC 2 Type 1.

Does Springer Health+ India have SOC 2 Type 2 certification ?

According to Rankiteo, Springer Health+ India does not hold a SOC 2 Type 2 certification.

Does Springer Health+ India comply with GDPR ?

According to Rankiteo, Springer Health+ India is not listed as GDPR compliant.

Does Springer Health+ India have PCI DSS certification ?

According to Rankiteo, Springer Health+ India does not currently maintain PCI DSS compliance.

Does Springer Health+ India comply with HIPAA ?

According to Rankiteo, Springer Health+ India is not compliant with HIPAA regulations.

Does Springer Health+ India have ISO 27001 certification ?

According to Rankiteo,Springer Health+ India is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Springer Health+ India operate in ?

Springer Health+ India operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Springer Health+ India have ?

Springer Health+ India employs approximately None employees people worldwide.

Does Springer Health+ India own any subsidiaries ?

Springer Health+ India presently has no subsidiaries across any sectors.

How many LinkedIn followers does Springer Health+ India have ?

Springer Health+ India's official LinkedIn profile has approximately 1,227 followers.

What is the NAICS classification code for Springer Health+ India ?

Springer Health+ India is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Springer Health+ India have a Crunchbase profile ?

No, Springer Health+ India does not have a profile on Crunchbase.

Does Springer Health+ India have a LinkedIn profile ?

Yes, Springer Health+ India maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/springer-healthplus-india.

How many cybersecurity incidents has Springer Health+ India experienced ?

As of June 4, 2026, Rankiteo reports that Springer Health+ India has not experienced any cybersecurity incidents.

How many peer or competitor companies does Springer Health+ India have ?

Springer Health+ India has an estimated 5,671 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

SHI

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Springer Health+ India Vendor Cyber Rating & Cyber Score

springerhealthplus.com

Add Your Compliance Badge

Since 1982, Springer Health+ has delivered trusted healthcare education and communications. Medical progress is more than just science, and with people at the core of everything we do, our expertise delivers information that is trusted worldwide. We are a forward-thinking, diverse agency specialising in medical communications and digital engagement. Our mission is to help the medical community not just keep up with science but move it forward. Springer Health + is part of Springer Nature.

SHI A.I CyberSecurity Scoring

Scoring History

SHI

Springer Health+ India CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

SHI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for SHI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Springer Health+ India in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Springer Health+ India in 2026.

Incident Types SHI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Springer Health+ India in 2026.

Incident History - SHI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Springer Health+ India Subsidiaries

Parent Company

SHI

Pharmaceutical Manufacturing

Website: https://springerhealthplus.com/

Company Size: 201-500 employees

No subsidiary data available for this company.

Loading…

Springer Health+ India Similar Companies

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Loading…

NEWS

Springer Health+ India CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 28, 2026 08:00 AM

Springer Nature Announces Leadership Transition in India

Springer Nature today announced a leadership transition within its India business as part of the company's ongoing efforts to strengthen its...

Read Article

October 31, 2025 07:00 AM

Springer Nature honours Indian editors at Journal Development Symposium 2025. Brings Together Leading Editors and Publishing Experts to Shape the Future of Research Integrity and AI in Scholarly Communication

The day long Journal Development Symposium 2025, organised by Springer Nature, brought together over 100 journal editors,...

Read Article

October 27, 2023 07:00 AM

IoT empowered smart cybersecurity framework for intrusion detection in internet of drones | Scientific Reports

The proposed system effectively detects cyber-attacks in drone networks by leveraging deep learning and machine learning techniques.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-10777

SUMMARY

A vulnerability was identified in ealpha072 Student-Management-System up to 01451bd7a2f58cdda07bd0b86e3967582e3ecd08. Affected by this issue is some unknown functionality of the file admin/config.php of the component Administrative Backend. Such manipulation leads to improper authentication. The attack may be performed from remote. The exploit is publicly available and might be used. This product utilizes a rolling release system for continuous delivery, and as such, version information for affected or updated releases is not disclosed. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-06-03

Updated

Date2026-06-03

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-10775

SUMMARY

A vulnerability was determined in sgl-project SGLang up to 0.5.11. Affected by this vulnerability is the function data_hash of the component Cache Handler. This manipulation causes denial of service. The attack is restricted to local execution. A high degree of complexity is needed for the attack. The exploitation appears to be difficult. The exploit has been publicly disclosed and may be utilized. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-03

Updated

Date2026-06-03

RISK INFORMATION (Score: 3.6)

cvss2

Base Score: 2.4

Complexity: HIGH

AV:L/AC:H/Au:S/C:N/I:P/A:P

cvss3

Base Score: 3.6

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:N/I:L/A:L

cvss4

Base Score: 1.1

Complexity: HIGH

CVSS:4.0/AV:L/AC:H/AT:N/PR:L/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

REFERENCES

CVE-2026-22055

SUMMARY

Active IQ OneCollect version 2.7.3 contains hard-coded credentials that could allow an authenticated attacker with low privileges to perform unauthorized AutoSupport operations.

Published

Date2026-06-03

Updated

Date2026-06-03

RISK INFORMATION (Score: )

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:L/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://security.netapp.com/advisory/ntap-20260603-0002

CVE-2026-22054

SUMMARY

Active IQ Config Advisor version 6.7.3 contains hard-coded credentials that could allow an authenticated attacker with low privileges to perform unauthorized AutoSupport operations.

Published

Date2026-06-03

Updated

Date2026-06-03

RISK INFORMATION (Score: )

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:L/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://security.netapp.com/advisory/ntap-20260603-0001

CVE-2026-10771

SUMMARY

A vulnerability was found in crmeb crmeb_java 1.4. Affected is the function RestTemplate.getForEntity of the file crmeb-common/src/main/java/com/zbkj/common/utils/RestTemplateUtil.java of the component base64 Qrcode Endpoint. The manipulation of the argument url results in server-side request forgery. The attack can be executed remotely. The exploit has been made public and could be used. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-06-03

Updated

Date2026-06-03

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…